Clinical Trials
24 trialsNCT06119581 2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07279935 2026-06-01
REVIVE
AstraZeneca
Phase 4 Recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06606847 2026-05-15
LADOGA
AstraZeneca
Phase 2 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT07162883 2025-09-09
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT05886075 2023-06-02
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT03085069 2023-02-16
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT03134872 2020-06-09
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03083743 2017-03-20
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection
Shanghai Gebaide Biotechnology Co., Ltd.
Phase 3 Unknown
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT01058785 2010-07-29
Phase II Study of Lucanixâ„¢ in Patients With Stages II-IV Non-Small Cell Lung Cancer
NovaRx Corporation
Phase 2 Completed
NCT00102505 2009-04-03
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
Pharmacyclics LLC.
Phase 1 Completed